Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow-up. However, significant variability exists in methods of pathologic assessment of response to NAST, and thus its interpretation for subsequent clinical decisions. Our international multidisciplinary working group was convened by the Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration and tasked to recommend practical methods for standardized evaluation of the post-NAST surgical breast cancer specimen for clinical trials that promote accurate and reliable designation of pathologic complete response (pCR) and meaningful characterization of residual disease. Recommendations include multidisciplinary communication; clinical marking of the tumor site (clips); and radiologic, photographic, or pictorial imaging of the sliced specimen, to map the tissue sections and reconcile macroscopic and microscopic findings. The information required to define pCR (ypT0/is ypN0 or ypT0 yp N0), residual ypT and ypN stage using the current AJCC/UICC system, and the Residual Cancer Burden system were recommended for quantification of residual disease in clinical trials.

Original languageEnglish (US)
Pages (from-to)1280-1291
Number of pages12
JournalAnnals of Oncology
Volume26
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Neoadjuvant Therapy
Clinical Trials
Breast Neoplasms
Interdisciplinary Communication
Residual Neoplasm
Surgical Instruments
Breast
Neoplasms
Therapeutics

Keywords

  • Breast cancer
  • Neoadjuvant systemic therapy
  • Pathologic assessment
  • Pathologic complete response
  • Residual disease
  • Response evaluation

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. / Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration.

In: Annals of Oncology, Vol. 26, No. 7, 01.07.2015, p. 1280-1291.

Research output: Contribution to journalArticle

Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. / Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. In: Annals of Oncology. 2015 ; Vol. 26, No. 7. pp. 1280-1291.
@article{b582f42a0c8246c3800192d92588ae76,
title = "Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration",
abstract = "Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow-up. However, significant variability exists in methods of pathologic assessment of response to NAST, and thus its interpretation for subsequent clinical decisions. Our international multidisciplinary working group was convened by the Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration and tasked to recommend practical methods for standardized evaluation of the post-NAST surgical breast cancer specimen for clinical trials that promote accurate and reliable designation of pathologic complete response (pCR) and meaningful characterization of residual disease. Recommendations include multidisciplinary communication; clinical marking of the tumor site (clips); and radiologic, photographic, or pictorial imaging of the sliced specimen, to map the tissue sections and reconcile macroscopic and microscopic findings. The information required to define pCR (ypT0/is ypN0 or ypT0 yp N0), residual ypT and ypN stage using the current AJCC/UICC system, and the Residual Cancer Burden system were recommended for quantification of residual disease in clinical trials.",
keywords = "Breast cancer, Neoadjuvant systemic therapy, Pathologic assessment, Pathologic complete response, Residual disease, Response evaluation",
author = "{Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration} and Veerle Bossuyt and E. Provenzano and Symmans, {W. F.} and Boughey, {J. C.} and C. Coles and G. Curigliano and Dixon, {J. M.} and Esserman, {L. J.} and G. Fastner and T. Kuehn and F. Peintinger and {Von Minckwitz}, G. and J. White and W. Yang and Sunil Badve and C. Denkert and G. MacGrogan and F. Penault-Llorca and G. Viale and D. Cameron and Davidson, {Nancy E.} and Martine Piccart and Larry Norton and Helena Earl and Emilio Alba and Ana Lluch and Joan Albanell and Keith Amos and V{\'e}ronique Becette and Wojciech Biernat and Herv{\'e} Bonnefoi and Aman Buzdar and Paul Cane and Sarah Pinder and Lesley Carson and Diana Dickson-Witmer and Gyungyub Gong and Jimmy Green and Hsu, {Chih Yi} and Tseng, {Ling Ming} and Judith Kroep and {Marilyn Leitch}, A. and Venetia Sarode and Eleftherios Mamounas and Marcom, {Paul Kelly} and Paolo Nuciforo and Soonmyung Paik and Vicente Peg and David Peston and Pierga, {Jean Yves}",
year = "2015",
month = "7",
day = "1",
doi = "10.1093/annonc/mdv161",
language = "English (US)",
volume = "26",
pages = "1280--1291",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

AU - Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration

AU - Bossuyt, Veerle

AU - Provenzano, E.

AU - Symmans, W. F.

AU - Boughey, J. C.

AU - Coles, C.

AU - Curigliano, G.

AU - Dixon, J. M.

AU - Esserman, L. J.

AU - Fastner, G.

AU - Kuehn, T.

AU - Peintinger, F.

AU - Von Minckwitz, G.

AU - White, J.

AU - Yang, W.

AU - Badve, Sunil

AU - Denkert, C.

AU - MacGrogan, G.

AU - Penault-Llorca, F.

AU - Viale, G.

AU - Cameron, D.

AU - Davidson, Nancy E.

AU - Piccart, Martine

AU - Norton, Larry

AU - Earl, Helena

AU - Alba, Emilio

AU - Lluch, Ana

AU - Albanell, Joan

AU - Amos, Keith

AU - Becette, Véronique

AU - Biernat, Wojciech

AU - Bonnefoi, Hervé

AU - Buzdar, Aman

AU - Cane, Paul

AU - Pinder, Sarah

AU - Carson, Lesley

AU - Dickson-Witmer, Diana

AU - Gong, Gyungyub

AU - Green, Jimmy

AU - Hsu, Chih Yi

AU - Tseng, Ling Ming

AU - Kroep, Judith

AU - Marilyn Leitch, A.

AU - Sarode, Venetia

AU - Mamounas, Eleftherios

AU - Marcom, Paul Kelly

AU - Nuciforo, Paolo

AU - Paik, Soonmyung

AU - Peg, Vicente

AU - Peston, David

AU - Pierga, Jean Yves

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow-up. However, significant variability exists in methods of pathologic assessment of response to NAST, and thus its interpretation for subsequent clinical decisions. Our international multidisciplinary working group was convened by the Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration and tasked to recommend practical methods for standardized evaluation of the post-NAST surgical breast cancer specimen for clinical trials that promote accurate and reliable designation of pathologic complete response (pCR) and meaningful characterization of residual disease. Recommendations include multidisciplinary communication; clinical marking of the tumor site (clips); and radiologic, photographic, or pictorial imaging of the sliced specimen, to map the tissue sections and reconcile macroscopic and microscopic findings. The information required to define pCR (ypT0/is ypN0 or ypT0 yp N0), residual ypT and ypN stage using the current AJCC/UICC system, and the Residual Cancer Burden system were recommended for quantification of residual disease in clinical trials.

AB - Neoadjuvant systemic therapy (NAST) provides the unique opportunity to assess response to treatment after months rather than years of follow-up. However, significant variability exists in methods of pathologic assessment of response to NAST, and thus its interpretation for subsequent clinical decisions. Our international multidisciplinary working group was convened by the Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration and tasked to recommend practical methods for standardized evaluation of the post-NAST surgical breast cancer specimen for clinical trials that promote accurate and reliable designation of pathologic complete response (pCR) and meaningful characterization of residual disease. Recommendations include multidisciplinary communication; clinical marking of the tumor site (clips); and radiologic, photographic, or pictorial imaging of the sliced specimen, to map the tissue sections and reconcile macroscopic and microscopic findings. The information required to define pCR (ypT0/is ypN0 or ypT0 yp N0), residual ypT and ypN stage using the current AJCC/UICC system, and the Residual Cancer Burden system were recommended for quantification of residual disease in clinical trials.

KW - Breast cancer

KW - Neoadjuvant systemic therapy

KW - Pathologic assessment

KW - Pathologic complete response

KW - Residual disease

KW - Response evaluation

UR - http://www.scopus.com/inward/record.url?scp=84940719491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940719491&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdv161

DO - 10.1093/annonc/mdv161

M3 - Article

VL - 26

SP - 1280

EP - 1291

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -